Prostate Cancer - Results from #24360

Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy - Abstract November 23, 2012

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era - Abstract November 23, 2012

Interstitial brachytherapy in localised prostate cancer: Executive summary of final report N04-02, Version 1.0 - Abstract November 22, 2012

The lived experience of men diagnosed with prostate cancer - Abstract November 22, 2012

The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: Challenges and solutions for physicians and patients - Abstract November 22, 2012

Cabazitaxel in metastatic castration-resistant prostate cancer - Abstract November 22, 2012

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy - Abstract November 22, 2012

Frequency of brain metastases from prostate cancer: An 18-year single-institution experience - Abstract November 22, 2012

Whole-body diffusion-weighted MRI compared with 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma - Abstract November 22, 2012

Anastomotic leak after robot-assisted laparoscopic radical prostatectomy: Evaluation with MDCT cystography with multiplanar reformatting and 3D display - Abstract November 21, 2012

The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms - Abstract November 21, 2012

Changes in apparent diffusion coefficient and T(2) relaxation during radiotherapy for prostate cancer - Abstract November 21, 2012

Interstitial brachytherapy in localized prostate cancer – update: Executive summary of final report N10-01, Version 1.0 - Abstract November 21, 2012

Diabetes mellitus and prostate cancer risk in Asian countries: A meta-analysis - Abstract November 21, 2012

Cabazitaxel (Jevtana): A novel agent for metastatic castration-resistant prostate cancer - Abstract November 20, 2012

Contemporary grading for prostate cancer: Implications for patient care - Abstract November 20, 2012

A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment - Abstract November 20, 2012

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer - Abstract November 20, 2012

The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer - Abstract November 20, 2012

Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management - Abstract November 20, 2012

Page 1219 of 1436